Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity

Sponsor
Loma Linda University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03598426
Collaborator
(none)
270
Enrollment
1
Location
3
Arms
41.8
Anticipated Duration (Months)
6.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is a single center, prospective, randomized, open-label study aimed at determining the most effective means of preventing hypersensitivity reactions in gynecologic oncology patients receiving paclitaxel infusions. The study will therefore provide clinicians with the best ways of preventing paclitaxel hypersensitivity reactions in their patients during treatment. Subjects will be randomized using the block randomization method into one of these three commonly used treatment methods:(1) Conventional method: oral dexamethasone (20 mg), taking 12 hours and 6 hours prior to paclitaxel infusion and intravenous administration of histamine-1 (H1), and a histamine-2 (H2)receptor antagonists administered 30 minutes prior to paclitaxel infusion. (2) Short-course method: intravenous dexamethasone (20 mg), administered concurrently with H1 and H2 antagonists, 30 minutes prior to paclitaxel infusion. (3) Combined method: oral dexamethasone (20 mg), taking 12 hours prior to treatment in addition to intravenous dexamethasone (20 mg), H1 and H2 receptor antagonists administered 30 minutes prior to paclitaxel infusion. The one-way analysis of variance (ANOVA) would be used to determine if there is any significant difference between the different strategies that are used to pre-medicate patients prior to paclitaxel infusion. P-values of less than 0.05 will be considered statistically significant.

Condition or DiseaseIntervention/TreatmentPhase
Phase 3

Detailed Description

One of the potentially serious and dose-limiting toxicities of paclitaxel is the development of hypersensitivity reactions (HSRs). Up to 42% of patients receiving paclitaxel experience an HSR, with serious (> grade 3) reactions observed in about 2% of patients. Paclitaxel prescribing information and many other references therefore strongly recommend pre-medicating patients who are to be treated with paclitaxel-containing regimen with a corticosteroid, a histamine-1 (H1), and a histamine-2 (H2) antagonist prior to paclitaxel infusion. This is done to help prevent or minimize the occurrence of HSRs that could be caused by treating patients with paclitaxel. However, the method and timing of administering these pre-medications (particularly in the case of dexamethasone) have not been standardized. The current and most commonly used methods of preventing paclitaxel HSR includes one of the following: 1. Administering oral dexamethasone (20 mg), 12 hours and 6 hours prior to paclitaxel infusion and intravenous administration of H1 and H2 receptor antagonists 30 minutes prior to paclitaxel infusion (Conventional method); 2. Administering intravenous dexamethasone (20 mg), concurrently with H1 and H2 antagonists, 30 minutes prior to paclitaxel infusion (Short-course method); 3. Administering oral dexamethasone (20 mg), 12 hours prior to treatment in addition to intravenous dexamethasone (20 mg), H1 and H2 receptor antagonists administered 30 minutes prior to paclitaxel infusion. The goal of this study is to do a single center, prospective, randomized, open-label study to determine the most effective method in preventing paclitaxel HSR among these three commonly used methods.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
270 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Single center, prospective, randomized, open-label studySingle center, prospective, randomized, open-label study
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Conventional Prophylactic Regimen of Oral Dexamethasone Versus Short-course Intravenous Dexamethasone in Preventing Paclitaxel-related Hypersensitivity Reactions in Breast and Gynecologic Oncology Patients
Actual Study Start Date :
Aug 8, 2018
Anticipated Primary Completion Date :
Jan 31, 2022
Anticipated Study Completion Date :
Jan 31, 2022

Arms and Interventions

ArmIntervention/Treatment
Active Comparator: Conventional

Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.

Drug: Dexamethasone
Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
Other Names:
  • Decadron
  • Active Comparator: Short-Course

    Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.

    Drug: Dexamethasone
    Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
    Other Names:
  • Decadron
  • Active Comparator: Combined

    Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.

    Drug: Dexamethasone
    Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
    Other Names:
  • Decadron
  • Outcome Measures

    Primary Outcome Measures

    1. Least incidence of any-grade-paclitaxel-HSR first cycle [1 to 3 HOURS]

      The treatment group that had the least incidence of any-grade-paclitaxel-HSR in the first cycle of chemotherapy treatment

    Secondary Outcome Measures

    1. Least incidence of any-grade-paclitaxel-HSR in the first and second cycles [1 to 3 HOURS]

      The treatment group that had the least incidence of any-grade-paclitaxel-HSR in the first and second cycles of chemotherapy treatment

    2. Least incidence of grade 3 or more paclitaxel-HSR in the first and second cycles [1 to 3 HOURS]

      The treatment group that had the least incidence of grade 3 or more paclitaxel-HSR in the first and second cycles of chemotherapy treatment

    3. Least incidence of any-grade-paclitaxel-HSR second cycle [1 to 3 HOURS]

      The treatment group that had the least incidence of any-grade-paclitaxel-HSR in the second cycle of chemotherapy treatment

    4. Least incidence of grade 3 or more paclitaxel-HSR first cycle [1 to 3 HOURS]

      The treatment group that had the least incidence of grade 3 or more paclitaxel-HSR in the first cycle of chemotherapy treatment

    5. Least incidence of grade 3 or more paclitaxel-HSR second cycle [1 to 3 HOURS]

      The treatment group that had the least incidence of grade 3 or more paclitaxel-HSR in the second cycle of chemotherapy treatment

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Adult female patients > 18 years of age

    2. Patients of the Loma Linda University Health (LLUH) gynecologic oncology and breast oncology service

    3. Confirmed breast or gynecologic cancer diagnosis of any stage and any gynecologic or breast malignancy

    4. Planned treatment with paclitaxel containing regimen either in the adjuvant setting or for palliation

    5. Planned treatment with paclitaxel should be for 3 or more cycles given as a weekly or every 3 weeks cycle

    6. Paclitaxel should be given as a monotherapy or as part of a combination regimen. If paclitaxel is part of a regimen containing other drugs, the following conditions must be met:

    7. Paclitaxel will be the first chemotherapy regimen to be infused when patient comes in for treatment

    8. Chemotherapy regimen that would be approved for the study are the following:

    1. Paclitaxel/ Carboplatin ii. Paclitaxel/Carboplatin/Bevacizumab iii. Paclitaxel/Cisplatin/Bevacizumab iv. Paclitaxel/Bevacizumab v. Paclitaxel/ Ifosfamide
    1. Paclitaxel/ Pazopanib
    1. Patients should have no prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel)

    2. The chemotherapy treatment should be at one of the LLUH Adult Cancer Centers

    3. The patient should be an English or Spanish speaking patient

    Exclusion Criteria:
    1. Patients who are not with the gynecologic or breast oncology service

    2. Patients who are with the gynecologic oncology or breast oncology service but are not receiving paclitaxel either as a monotherapy or in combination with other regimen

    3. Patients who have had prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel)

    4. Patients who are currently on steroid therapy and it is anticipated that therapy will not be discontinued at least a week prior to start of chemotherapy

    5. Patients with autoimmune diseases, malignancies, and any other co-morbid condition that might require steroid therapy during chemotherapy. This includes, but not limited to:

    6. Crohn's disease

    7. Immune thrombocytopenia

    8. Lupus nephritis

    9. Multiple sclerosis

    10. Primary brain tumors

    11. Multiple Myeloma

    12. Hodgkin's Lymphoma

    13. Patients with uncontrolled diabetes or diabetic or pre-diabetic patients with baseline A1C levels > 8.5

    14. Patients who are allergic to diphenhydramine and/or dexamethasone

    15. Non-English and Non-Spanish speaking patients

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Loma Linda University Cancer CenterLoma LindaCaliforniaUnited States92354

    Sponsors and Collaborators

    • Loma Linda University

    Investigators

    • Principal Investigator: Linda Hong, MD, Loma Linda University Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Loma Linda University
    ClinicalTrials.gov Identifier:
    NCT03598426
    Other Study ID Numbers:
    • 5180198
    First Posted:
    Jul 26, 2018
    Last Update Posted:
    May 13, 2021
    Last Verified:
    May 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 13, 2021